Invention Grant
US09580422B2 Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
有权
同位素标记的三唑并吡啶11-β羟基类固醇脱氢酶I型抑制剂
- Patent Title: Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type I inhibitors
- Patent Title (中): 同位素标记的三唑并吡啶11-β羟基类固醇脱氢酶I型抑制剂
-
Application No.: US15031301Application Date: 2014-10-21
-
Publication No.: US09580422B2Publication Date: 2017-02-28
- Inventor: Yaofeng Cheng , Weiqi Chen , Brad D. Maxwell , Bach D. Tran , Jun Li
- Applicant: BRISTOL-MYERS SQUIBB COMPANY
- Applicant Address: US NJ Princeton
- Assignee: Bristol-Myers Squibb Company
- Current Assignee: Bristol-Myers Squibb Company
- Current Assignee Address: US NJ Princeton
- Agent Elliott Korsen
- International Application: PCT/US2014/061509 WO 20141021
- International Announcement: WO2015/061272 WO 20150430
- Main IPC: A61K31/44
- IPC: A61K31/44 ; C07D401/00 ; C07D471/04 ; C07B59/00 ; A61K31/437
Abstract:
Novel compounds are provided which are 11-beta-hydroxysteroid dehydrogenase type I inhibitors. 11-beta-hydroxysteroid dehydrogenase type I inhibitors are useful in treating, preventing, or slowing the progression of diseases requiring 11-beta-hydroxysteroid dehydrogenase type I inhibitor therapy. These novel compounds of formula I: or stereoisomers or pharmaceutically acceptable salts thereof, wherein R* is an isotopically labeled hydroxypropyl moiety.
Public/Granted literature
- US20160257680A1 ISOTOPICALLY LABELED TRIAZOLOPYRIDINE 11-BETA HYDROXYSTEROID DEHYDROGENASE TYPE I INHIBITORS Public/Granted day:2016-09-08
Information query
